Source: SiliconRepublic

Sitryx: Biopharma firm with Irish link signs deal with Eli Lilly potentially worth $880m

Based in the UK and co-founded by Trinity's Prof Luke O'Neill, biotech start-up Sitryx will develop four compounds to treat autoimmune diseases.The post Biopharma firm with Irish link signs deal with Eli Lilly potentially worth $880m appeared first on Silicon Republic.

Read full article »

Sitryx's Competitors | Sitryx's News | Sitryx's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Neil Weir

CEO Approval Rating

86/100

Sitryx is an England-based biopharmaceutical company that researches and develops immune cell metabolism therapies for the treatment of chronic autoimmune diseases and cancer.